It’s crucial for accountable care organizations to not only understand what value-based purchasing is, but for everyone to be on the same page as far as the expectations involved and what exactly it takes to get there, said Brian Marcotte, president and CEO of The National Business Group on Health.
It’s crucial for accountable care organizations (ACOs) to not only understand what value-based purchasing is, but for everyone to be on the same page as far as the expectations involved and what exactly it takes to get there, said Brian Marcotte, president and CEO at The National Business Group on Health.
Transcript (slightly modified)
How do you evaluate value-based purchasing?
Well, I think the challenge with value-based purchasing is that it’s a phrase that a lot of people don’t understand right now and I think this is one of those areas where it’s critical to get an alignment on what do we mean by value-purchasing and what can you expect from a network perspective, from a care model perspective, from a population health management and the financing model — what does all of that mean in a value-based purchasing scenario.
And that there’s a journey that these ACO’s go along as they evolve and they are able to take on risk, that they are able to do population health management and we need to educate employers so they can articulate back to the market what they expect and have that alignment be there as they’re talking to providers and as they’re talking to health plans so everybody’s on the same page and everybody knows what the ask is and know what it takes to get there.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More